Hims & Hers Health (NYSE:HIMS) Stock Price Down 0.4% - Here's What Happened

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) dropped 0.4% during trading on Monday . The company traded as low as $39.80 and last traded at $40.68. Approximately 19,737,321 shares changed hands during trading, an increase of 17% from the average daily volume of 16,818,933 shares. The stock had previously closed at $40.82.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Morgan Stanley cut their price target on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 29th. Truist Financial dropped their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $36.92.

Hims & Hers Health Price Performance

The firm has a market cap of $9.33 billion, a P/E ratio of 96.46 and a beta of 1.84. The company's 50-day simple moving average is $32.21 and its 200 day simple moving average is $31.56.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity

In other news, insider Irene Becklund sold 2,203 shares of the company's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the transaction, the insider now owns 8,007 shares of the company's stock, valued at approximately $230,441.46. This represents a 21.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $38.92, for a total value of $450,732.52. Following the completion of the sale, the chief financial officer now owns 112,933 shares in the company, valued at approximately $4,395,352.36. The trade was a 9.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 662,081 shares of company stock valued at $26,241,044. 17.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth about $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. increased its position in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.